27/07/2026
An important milestone for research into one of the world's priority emerging infectious diseases.
Clinical trials like UMIT-2 are essential for building the evidence needed to improve patient outcomes, while strengthening international research partnerships and preparedness for future infectious disease threats.
Congratulations to everyone involved. Read more in the post below.
In a major milestone in the global fight against Crimean-Congo haemorrhagic fever (CCHF), the first participant has now been randomised in the UMIT-2 clinical trial at Sivas Cumhuriyet University, Türkiye.
The UMIT-2 trial, sponsored by LSTM and funded by the UK Medical Research Council, is the first multi-country, multi-site therapeutic clinical trial for CCHF.
Despite being recognised as a priority pathogen, there are currently no licensed antiviral therapies proven to improve outcomes for patients. This study marks an important advancement in CCHF research, bringing together partners across Türkiye, Iraq and the UK to evaluate urgently needed antiviral treatments for this high-priority emerging disease.
Find out more: https://lstm.ac/UMIT2-trial-news